Exzeo Spent a $12 Million Buyback in Six Weeks. Friday Afternoon It Authorized $25 Million More.

by Ellis Vance · August 16, 2026

Small-Cap Markets Correspondent, The SmallCap Signal

Exzeo Group Inc. (NYSE: XZO) disclosed after Friday's closing bell that its board had authorized a program to purchase up to $25 million of the company's common shares, subject to market conditions, with a term of one year. The release crossed Business Wire on Friday, Aug. 14, carrying a 4:15 p.m. ET timestamp — 20:15 UTC in the page's own publication metadata — which puts it after the market had already stopped trading for the week.

A $25 million authorization is a modest figure set against the $333.8 million of cash, cash equivalents and investments Exzeo reported at June 30. What makes it worth a look is the calendar. Exzeo authorized its previous buyback on May 26 and, according to the company's second-quarter Form 10-Q, finished spending it on July 8 — about six weeks later.

The August release is spare. It says the program permits open-market purchases, block transactions, privately negotiated transactions and Rule 10b5-1 trading programs, that repurchases will be made in compliance with Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, that the timing and amount of any purchases are determined at management's discretion and depend on business, economic and market conditions, and that the program "has a term of one year, does not obligate Exzeo to acquire a specific number of shares of common stock, and may be canceled or suspended at any time without notice." It carries no quotation from a named executive, and it does not mention the program that preceded it.

The May 26 release was different in tone. It announced an authorization of up to $12 million, effective immediately, and said the company had adopted a Rule 10b5-1 trading plan so a third-party broker could buy during blackout periods subject to price, volume and timing constraints. Paresh Patel, Chief Executive Officer of Exzeo, said in that release: "This share repurchase program reflects our confidence in the long-term value of Exzeo Group. The company continues to generate strong positive cash flow and maintains a debt-free balance sheet." Patel also described the buyback in that release as allocating a small portion of the company's earnings to acquiring its own shares.

The quarterly report filed for the period ended June 30 puts numbers on what the plan actually did. Exzeo repurchased 726,828 shares for approximately $10.0 million during the first half of 2026, then bought 107,422 more shares for roughly $2.0 million between July 1 and July 8, completing the authorization. Total: 834,250 shares for $12.0 million. The two tranches reconcile to the full authorized amount, and the blended arithmetic works out to an implied average of about $14.38 a share — well below the $21.00 at which Exzeo sold stock to the public in November 2025. The filing itself states no average price; that figure is division, not disclosure.

Against the whole company, that is a small bite. Exzeo reported 90,085,918 shares of common stock outstanding as of the July 31 cover date of its 10-Q. The 834,250 shares repurchased amount to something under 1 percent of that count.

Against the part of the company that actually trades, it is a much larger number. Exzeo's IPO prospectus, filed with the SEC in November 2025, shows the company sold 8,000,000 shares at $21.00 each, with a 30-day underwriters' option for up to 1,200,000 more, leaving 90,775,789 shares outstanding after the offering, or 91,975,789 if that option were exercised in full. Adding the 834,250 repurchased shares back to the 90,085,918 the 10-Q reports outstanding at July 31 gives about 90.9 million — below the 91,975,789 that full exercise would have produced, which indicates the option was not taken up in full. Measured against the 8 million shares sold in the deal, the first buyback took back better than a tenth of the public tranche — about 10.4 percent — in six weeks.

That arithmetic has a second consequence, and it runs through the majority holder. Exzeo was HCI Group Inc.'s technology division before the IPO, and HCI remains its controlling shareholder. In its own second-quarter Form 10-Q, HCI reported owning approximately 83.1 percent of Exzeo as of June 30, 2026. Exzeo's prospectus had contemplated HCI holding about 81.54 percent after the offering assuming the underwriters exercised their option in full — a condition the prospectus states explicitly, and one the share counts above suggest was not met. Repurchasing shares mechanically raises a continuing holder's percentage without that holder purchasing anything; the buyback and HCI's rising share of the company are the same transaction seen from two sides.

Working from those disclosed figures, roughly 16.9 percent of Exzeo — on the order of 15 million shares — sits outside HCI's stake. A $25 million program executed at the implied average price of the first one would take in something close to 1.7 million shares. Whether it gets executed at that pace, that price, or at all is not something the release commits to.

The balance sheet supports the spending. Exzeo's Aug. 6 results release reported second-quarter revenue of $57.8 million against $56.1 million a year earlier, net income of $23.3 million against $21.7 million, and adjusted EBITDA of $29.9 million against $29.6 million. Cash, cash equivalents and investments stood at $333.8 million; the 10-Q shows $136.7 million of that in cash and cash equivalents at June 30. Managed premium rose to $1.40 billion from $1.22 billion, and annual recurring revenue reached $210.7 million. The release contained no forward guidance.

One line in that release explains why the buyback is more than housekeeping. Exzeo reported earnings of $0.26 a share, basic and diluted — the identical figure it posted in the second quarter of 2025, even though net income rose about 7 percent between the two periods. The share count is larger than it was a year ago, because a year ago Exzeo had not yet sold stock to the public. Share repurchases are the lever that moves that denominator back, and the first program moved it by less than a percentage point.

The revenue behind those earnings comes from one place. The IPO prospectus says Exzeo "has derived substantially all of its revenues to date" from customers owned or managed by HCI and its subsidiaries. The concentrations note in the second-quarter 10-Q is narrower but points the same way: two related-party customers each accounted for more than 10 percent of total revenue and together made up approximately 85.6 percent of revenue for the quarter, and about 86.9 percent for the first six months of 2026. Because that note counts only the customers above the 10 percent threshold, it is a floor on related-party revenue rather than the whole of it. Exzeo's platform of configurable applications for quoting, underwriting, policy administration and claims is sold to insurance carriers; so far the carriers buying it are overwhelmingly HCI's.

Several things the August release does not say are worth marking. It sets no per-quarter pace, no price floor or ceiling, and no minimum. It does not state whether a Rule 10b5-1 plan has been adopted for this authorization, only that such programs are among the permitted methods. And it does not reference the completed $12 million program at all, which means investors comparing the two have to do it from the filings rather than from the announcements. The next place the answer will appear is the third-quarter Form 10-Q.

US markets have been closed since Friday's bell, so nothing has traded against the announcement. The first test of it comes at Monday's open.